Research on Ginseng Polysacchride Injection Add DC Treatment in Th1/Th2 of NSCLC and CRC Patients Under Theory of Treating Different Diseases with Same Method

MA Jun-jie; XU Bin; LIU Hui-ping

doi:10.13422/j.cnki.syfix.2014080203

您当前的位置：

首页 >

文章列表页 >

Research on Ginseng Polysacchride Injection Add DC Treatment in Th1/Th2 of NSCLC and CRC Patients Under Theory of Treating Different Diseases with Same Method

更新时间：2024-01-04

- Research on Ginseng Polysacchride Injection Add DC Treatment in Th1/Th2 of NSCLC and CRC Patients Under Theory of Treating Different Diseases with Same Method
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 8, Pages: 203-206(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfix.2014080203
  CLC：
- Published：2014
- 稿件说明：
移动端阅览
MA Jun-jie, XU Bin, LIU Hui-ping. Research on Ginseng Polysacchride Injection Add DC Treatment in Th1/Th2 of NSCLC and CRC Patients Under Theory of Treating Different Diseases with Same Method[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 203-206.
DOI：

MA Jun-jie, XU Bin, LIU Hui-ping. Research on Ginseng Polysacchride Injection Add DC Treatment in Th1/Th2 of NSCLC and CRC Patients Under Theory of Treating Different Diseases with Same Method[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(8): 203-206. DOI： 10.13422/j.cnki.syfix.2014080203.

摘要

目的：探索人参多糖注射液（GPS）联合树突状细胞（DC）对非小细胞肺癌（NSCLC）、大肠癌（CRC）异病同治的Th1/Th2相关肿瘤免疫调节机制。方法：80例NSCLC，CRC患者（各40例）按照不同疾病及治疗方法随机分4组：NSCLC对照组（DC治疗）、NSCLC研究组（GPS联合DC治疗）、CRC对照组（DC治疗）、CRC研究组（GPS联合DC治疗），每组各20例。4组肿瘤患者干预前后分别检测血清γ干扰素（INF-γ）、白细胞介素4（IL-4）、白细胞介素2（IL-2）、白细胞介素5（IL-5）。结果：4组肿瘤患者治疗前后比较，Th1（INF-γ，IL-2）及Th1/Th2（INF-γ/IL-4，IL-2/IL-5）升高，Th2（IL-4，IL-5）降低（P<0.01）；4组肿瘤患者治疗后比较，Th1（INF-γ、IL-2）及Th1/Th2（INF-γ/IL-4，IL-2/IL-5）：NSCLC研究组>NSCLC对照组，CRC研究组>CRC对照组（P<0.05），Th2（IL-4、IL-5）：NSCLC对照组>NSCLC研究组，CRC对照组>CRC研究组（P<0.05）。结论：GPS联合DC对此两类肿瘤患者Th1/Th2皆具有不同程度调节作用，此为其异病同治作用机制之一；GPS对DC免疫调节具有协同作用。

Abstract

Objective: To explore the mechanism of Ginseng Polysacchride injection(GPS) add dendritic cells(DC) effect on Th1/Th2 of non-small cell lung cancer(NSCLC) and colorectal cancer(CRC) patients. Method: Eight cases of NSCLC and CRC patients were divided into four groups randomly (NSCLC control group

NSCLC research group

CRC control group

CRC research group)

20 cases in each group. Using DC or GPS add DC treatment. Detect interferon-γ(INF-γ)

interleukin-4(IL-4)

IL-2 and IL-5 in the four groups before and after treatment. Result: Before and after treatment

Th1(INF-γ

IL-2)and Th1/Th2(INF-γ/IL-4

IL-2/IL-5) were increased and Th2(IL-4

IL-5)was decreased in four cancer groups(P<0.01). After treatment

Th1(INF-γ

IL-2) and Th1/Th2(INF-γ/IL-4

IL-2/IL-5) were showed:NSCLC research group>NSCLC control group and CRC research group>CRC control group(P<0.05);Th2(IL-4

IL-5) was showed:NSCLC control group>NSCLC research group and CRC control group>CRC research group(P<0.05). Conclusion: GPS add DC treatment has different degree of Th1/Th2 regulation in NSCLC and CRC patients

this is one of the mechanisms of treating different diseases with the same method;GPS have the assistant to DC in adjusting the immunity of cancer patients.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰